Get the Stockscreener App
2.20
8.91%
0.18
After Hours:
2.15
-0.05
-2.27%
Caribou Biosciences Inc stock is traded at $2.20, with a volume of 2.10M.
It is up +8.91% in the last 24 hours and up +24.29% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
See More
Previous Close:
$2.02
Open:
$2.04
24h Volume:
2.10M
Relative Volume:
1.72
Market Cap:
$182.92M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.2088
EPS:
-1.82
Net Cash Flow:
$-104.90M
1W Performance:
+12.24%
1M Performance:
+24.29%
6M Performance:
-25.93%
1Y Performance:
-61.74%
1-Day Range:
$2.00
$2.20
1-Week Range:
$1.91
$2.515
52-Week Range:
$1.50
$8.33
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
2.20 | 182.92M | 34.48M | -102.07M | -104.90M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Caribou Biosciences price target lowered to $6 from $30 at Citi - MSN
Caribou Biosciences Reports Q3 2024 Financial Results - TipRanks
Caribou Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Caribou Biosciences CEO to Present at Major Healthcare Conferences on CRISPR Advances | CRBU Stock News - StockTitan
The Rosen Law Firm, P.A. Announces Proposed Class Action - GlobeNewswire
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Caribou Biosciences, Inc. – CRBU - GlobeNewswire Inc.
Steven Cohen's Strategic Acquisition in Caribou Biosciences Inc - GuruFocus.com
Caribou Biosciences (NASDAQ:CRBU) Receives Buy Rating from HC Wainwright - MarketBeat
PFM Health Sciences, LP Increases Stake in Caribou Biosciences I - GuruFocus.com
Caribou Biosciences' SWOT analysis: biotech stock's potential amid clinical trials - Investing.com Australia
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates - MSN
Brokers Set Expectations for CRBU FY2024 Earnings - Defense World
Leerink Partnrs Issues Optimistic Forecast for CRBU Earnings - Defense World
What is Leerink Partnrs' Forecast for CRBU FY2024 Earnings? - MarketBeat
CRBU FY2024 EPS Increased by Brookline Capital Management - MarketBeat
Caribou Biosciences, Inc. (NASDAQ:CRBU) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
Caribou Biosciences (NASDAQ:CRBU) Announces Quarterly Earnings Results - MarketBeat
Caribou Biosciences (NASDAQ:CRBU) vs. Sutro Biopharma (NASDAQ:STRO) Financial Analysis - Defense World
Caribou Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Caribou Biosciences earnings beat by $0.07, revenue fell short of estimates - Investing.com UK
Caribou Biosciences reports Q3 EPS (38c), consensus (45c) - TipRanks
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - StockTitan
CRISPR Technology Market Report 2024, with Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and MoreResearchAndMarkets.com | FinancialContent Business Page - Financial Content
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry - Simply Wall St
Vanguard Group Inc's Strategic Acquisition in Caribou Biosciences Inc - GuruFocus.com
Critical Analysis: Caribou Biosciences (NASDAQ:CRBU) & Titan Pharmaceuticals (NASDAQ:TTNP) - Defense World
Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock? - Insider Monkey
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Bought by Exchange Traded Concepts LLC - Defense World
STATE STREET CORP's Strategic Acquisition in Caribou Biosciences Inc - GuruFocus.com
Following a 49% decline over last year, recent gains may please Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional owners - Simply Wall St
Its Stock Has Paid Off Big Time For Caribou Biosciences Inc - SETE News
How to interpret Caribou Biosciences Inc (CRBU)’s stock chart patterns - US Post News
Daily Market Movement: Caribou Biosciences Inc (CRBU) Sees a 5.56 Increase, Closing at 1.90 - The Dwinnex
Dimensional Fund Advisors LP Has $4.30 Million Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - MarketBeat
A better buy-in window may exist right now for Caribou Biosciences Inc (CRBU) - SETE News
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Purchased by Green Alpha Advisors LLC - Defense World
Caribou Biosciences Inc (CRBU) presents a great opportunity, but the stock is slightly undervalued - US Post News
Analyzing Ratios: Caribou Biosciences Inc (CRBU)’s Financial Story Unveiled - The Dwinnex
Susquehanna Fundamental Investments LLC Sells 91,637 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Acquired by American Century Companies Inc. - Defense World
Point72 DIFC Ltd Purchases 23,995 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Point72 Asset Management L.P. Decreases Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - MarketBeat
Point72 Asset Management L.P. Sells 1,241,478 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
1,482,900 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Bought by Renaissance Technologies LLC - Defense World
31,831 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Purchased by Point72 Asia Singapore Pte. Ltd. - Defense World
Taking on analysts’ expectations and winning: Caribou Biosciences Inc (CRBU) - SETE News
Daily Market Movement: Caribou Biosciences Inc (CRBU) Sees a 2.06 Increase, Closing at 1.98 - The Dwinnex
Caribou Biosciences Inc (CRBU) presents a great opportunity, but the stock is slightly overvalued - US Post News
Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing - Seeking Alpha
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):